ALSO NOTED: Forest files suit against Caraco; Cephalon R&D chief sees potential; and much more...

> Forest Laboratories is suing Caraco Pharmaceutical Laboratories claiming patent infringements on the antidepressant Lexapro. Report [1]

> Cephalon's R&D chief says Wall Street is underestimating the market potential of its experimental cancer therapies. Report [2]

> Germany's GPC Biotech has filed another part of its marketing application for the cancer therapy satraplatin. Report [3]

> Kos Pharmaceuticals has filed a drug application with the FDA for a new form of its Niaspan cholesterol therapy. Report [4]

> Array BioPharma has pocketed $18 million of the $32 million it will receive from a sale-leaseback deal. Report [5]

And Finally… A new study says that people taking a potion made from a hallucinogenic mushroom reported mystical experiences that led to behavioral changes that lasted for weeks. Researchers urged people not to try to replicate this study at home. Article [6]